PDF Cover

Pralsetinib Market

Pralsetinib Market

The market for Pralsetinib was estimated at $1.10 billion in 2024; it is anticipated to increase to $1.9 billion by 2030, with projections indicating growth to around $2.9 billion by 2035.

Report ID:DS1802140
Author:Debadatta Patel - Senior Consultant
Published Date:April 2025
Datatree
Life Science
Pharmaceutical
Pralsetinib
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Pralsetinib Market Outlook

Revenue, 2024

$1.1B

Forecast, 2034

$2.6B

CAGR, 2024 - 2034

9.1%
The Pralsetinib industry revenue is expected to be around $1.2 billion in 2025 and expected to showcase growth with 9.1% CAGR between 2025 and 2034. Such robust growth can primarily be attributed to the substantial demand for Pralsetinib, being largely driven by its inherent benefits in the treatment of cancer. Increases in the incidences of lung cancer, coupled with ongoing research and development activities in the cancer therapeutics domain, have further facilitated the rapid uptake of Pralsetinib in the healthcare sector. Progressing advancements, combined with the emergent trends in personalized medicine and precision diagnostics, are steadily fueling the significant relevance and market momentum of Pralsetinib worldwide.

Renowned as a highly effective, selective RET inhibitor, Pralsetinib has been explicitly designed for the treatment of cancers that express aberrant RET signals. Offering ample potential in oncology therapeutics, it has demonstrated noteworthy efficacy for various RET fusion-positive cancers, including NSCLC and thyroid cancers. Application trends indicate an increasing reliance on Pralsetinib for the treatment of solid tumors and malignancies, owing to the drugs competence in disrupting the oncogenic RET signaling.

Pralsetinib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Pralsetinib market is projected to grow from $1.1 billion in 2024 to $2.6 billion in 2034. This represents a CAGR of 9.1%, reflecting rising demand across Lung Cancer Treatment, Advanced Thyroid Cancer Treatment and High-Grade Neuroendocrine Cancer Treatment.
  • Blueprint Medicines, Genentech Inc, Roche Holding AG are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Germany are the top markets within the Pralsetinib market and are expected to observe the growth CAGR of 6.6% to 9.6% between 2024 and 2030.
  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.7% to 11.4%.
  • Transition like Personalized Treatment Approach is expected to add $200.0 million to the Pralsetinib market growth by 2030
  • The Pralsetinib market is set to add $1.5 billion between 2024 and 2034, with manufacturer targeting Adult Patients & Pediatric Patients Target Population projected to gain a larger market share.
  • With Increase in ret-altered cancers, and Emerging personalized medicine, Pralsetinib market to expand 139% between 2024 and 2034.
pralsetinib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Pralsetinib

Apart from its core functionality, investing in technological innovation in the administration of Pralsetinib would be a significant.Refining the drug delivery system to enhance the user experience and drug effectiveness could lead to increased market share.

Growth Opportunities in North America and Europe

North America Outlook

Being a major hub for pharmaceutical innovation, North America presents a significant market potential for Pralsetinib. This is driven by an ever-increasing patient pool for non-small cell lung cancer and thyroid cancer, two critical application region's for Pralsetinib. Furthermore, the region showcases high competition levels due to the presence of top pharma giants focused on cancer therapeutics. However, the vast potential and heightened competition also unlock opportunities for collaborations, mergers, and acquisitions, helping companies improve their drug portfolios and maximizing patient outreach. Another critical driver for Pralsetinibs market in this region is the increasing support for research and development around targeted therapies.

Europe Outlook

Parallel to North America, Europe carries significant market potential for Pralsetinib. With advanced healthcare systems across much of the region, There is notable demand for cutting-edge cancer therapeutics, thus providing high-growth opportunities. The competition also remains high here, chiefly from companies that specialize in oncology, thus invigorating the market further. The primary market driver here is Europe's changing demographics, with an aging population that increasingly requires therapeutic interventions in cancer. Finally, making a strong case for Pralsetinib in Europe are the large-scale initiatives to fund research and development activities in oncology, further bolstering its adoption potential.

Market Dynamics and Supply Chain

01

Driver: Increase in RET-Altered Cancers

Oncology research has also identified an upturn in the incidence of cancers with alterations in RET , specifically thyroid cancer and non-small cell lung cancer. This surge spurs the demand for Pralsetinib, a potent RET inhibitor, designed to target mutations that lead to uncontrolled cell growth in RET-altered cancers. Pralsetinib, with its inhibitive action on RET-altered cancers, can also potentially become an invaluable weapon in the fight against these proliferating cancers.
With the advancements in genomics and precision medicine, therapies tailored to a patients genetic profile have also gained prominence. The trend of personalized oncology treatments has also driven the need for targeted therapies like Pralsetinib, a solution congruent with the precision medicine trend. It offers a targeted approach to treat patients with specific RET rearrangements, thus offering a new hope in personalized medicine.
02

Restraint: High Cost and Limited Accessibility of Pralsetinib

Expensive and limited access to medical and cancer treatments inhibit widespread acceptance of newer therapies like Pralsetinib. Patients in lower-income brackets may not only have adequate resources to pursue cutting-edge treatments, thereby restraining the market expansion. Unless Pralsetinib becomes more accessible and affordable, a large segment of the population may remain untreated, impacting the market demand dynamics.
03

Opportunity: Catering to Untapped Market Segments and Strategic Collaborations With Health Organizations

Pralsetinib, with its unique ability to treat patients with non-small cell lung cancer and thyroid cancer, holds untapped opportunities in developing markets where such treatment is still nascent. The expansion into these markets could potentially drive robust growth for Pralsetinib, as the incidence of these cancers is on the rise globally.
The success of Pralsetinib lies in its collaboration with different public and private health organizations. A partnership with oncology research centers could facilitate extensive studies and trials, strengthening its standing in the cancer treatment landscape. By leveraging these collaborations, Pralsetinib could ensure wider reach and acceptance.
04

Challenge: Regulatory Hurdles and Delays

Approval of investigational drugs like Pralsetinib can be a lengthy and complex process, sometimes taking several years for regulatory clearance with the need for considerable evidence demonstrating safety and efficacy. Frequent changes in pharmaceutical regulations add to these delays further. These obstacles, combined with a lack of synchronized regulatory guidelines across different geographies, significantly curb the growth and adoption of Pralsetinib in various potential markets.

Supply Chain Landscape

1
Raw Material Procurement

Carbosynth

Rgenta Therapeutics

2
API Synthesis

WuXi AppTec

Johnson Matthey

3
Drug Formulation

Blueprint Medicines

KeyTec

4
Retail & Distribution

Celgene Corporation

Novartis

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Pralsetinib in Lung Cancer Treatment, Advanced Thyroid Cancer Treatment & High-Grade Neuroendocrine Cancer Treatment

Lung Cancer Treatment

Leveraged as a therapeutic solution for lung cancer treatment, Pralsetinib targets the rearranged during transfection gene mutations found in 1-2% of patients. This targeted therapy is effective because it directly attacks RET mutated cells, resulting in fewer adverse side effects compared to traditional cancer treatments. BluePrint Medicines, the manufacturer of Pralsetinib, leads the market in this niche, delivering exceptional efficacy and tolerability in solid tumors with RET mutations.

High-Grade Neuroendocrine Cancer Treatment

Pralsetinib also holds promise in combating high-grade neuroendocrine cancers, aggressively attacking RET-rearranged tumors. These specific cancers are alarmingly resistant to conventional chemotherapies, making Pralsetinib a beacon of hope for patients. BluePrint Medicines has made significant strides in this territory, hence solidifying its market leadership.

Advanced Thyroid Cancer Treatment

Pralsetinib is breaking boundaries in treating advanced thyroid cancer, particularly when radioactive iodine has failed. Its specific genetic targeting approach offers improved response and a significant survival rate. This application further fortifies BluePrint Medicines position in the market, offering a compelling treatment option for challenging cases.

Recent Developments

December 2024

The FDA granted full approval to Pralsetinib, produced by Blueprint Medicines, for the treatment of individuals previously treated for metastatic RET-fusion positive non-small cell lung cancer.

October 2024

Blueprint Medicines established a strategic partnership with Roche, aiming to make Pralsetinib available globally, underpinning its significance in oncology treatments.

August 2024

Phase III clinical trial data published by Blueprint Medicines revealed Pralsetinib shows promising results in advanced thyroid cancer patients with RET alteration.

Pralsetinib, a select inhibitor of the rearranged during transfection proto-oncogene, gained traction in the robust pharmaceutical industry. Wit high efficacy and targeted approach, its rapidly emerging at the frontier of groundbreaking cancer therapies, specifically for RET fusion-positive non-small cell lung cancer and medullary thyroid cancer.

Impact of Industry Transitions on the Pralsetinib Market

As a core segment of the Pharmaceutical industry, the Pralsetinib market develops in line with broader industry shifts. Over recent years, transitions such as Personalized Treatment Approach and Utilizing AI in Drug Development have redefined priorities across the Pharmaceutical sector, influencing how the Pralsetinib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Personalized Treatment Approach

As a drug designed to target specific genetic mutations, Pralsetinib represents a significant shift in the paradigm of lung cancer treatment, from a onesizefitsall approach towards personalized therapy. This novel therapeutic option targets RET fusionpositive nonsmall cell lung cancer, genetically profiled to tailor treatment specifically for the patients mutation. By shifting towards a personalized medicine concept, Pralsetinib has brought a fresh dynamic within the pharmaceutical and healthcare industries, encouraging research and development of more mutationspecific drugs, promoting precision in treatment and improving patient outcomes. This industry transition is expected to add $200 million in the industry revenue between 2024 and 2030.
02

Utilizing AI in Drug Development

The development of Pralsetinib exemplifies how the application of AI algorithms can uncover new drug potentials hidden within vast troves of medical and genetic data. Using ML and predictive modeling, pharmaceutical companies, including those behind Pralsetinib, are streamlining drug discovery processes, reducing costs and improving the success rates of clinical trials.

Related Reports

Loading related reports...